ASSESSMENT AND APPRAISAL IN THE NETHERLANDS
Author(s)
Delwel GO1, Goettsch WG1, Cucic C2, Steenland E2, Terhell L2, Vingerhoed-van Aken BE21CVZ Healthcare Insurance Board, Diemen, Netherlands, 2Netherlands Organisation for Health Research and Development (ZonMw), The Hague, Netherlands
ORGANIZATION: This joint presentation of the Netherlands Organization for Health Research and Development and the Netherlands Healthcare Insurance Board will introduce the support structures for HTA in the country and its use when deciding on the composition of the insurance package. PROBLEM OR ISSUE ADDRESSED: and GOALS: Design and results of the Health Care Efficiency Research Program including early evaluation, effects and costs, implementation and high costs /orphan drugs research will be presented. The role of the Board in safeguarding and developing public preconditions for the health care insurance system will be delineated. Focusing on insurance package management, selection and prioritization of the topics will be explained. Processes in place for collection of HTA information, including coordination between research and package agenda as well as use of national and international methodology and results are discussed. OUTCOMES ITEMS USED IN THE DECISION: Through presentation of selected diseases / conditions and their treatments the pathway from research to package decision will be highlighted. In addition, the role of the advisory committees of the Board, including pharmaceutical, package clarification and package advise are explained. And the relation between the Insurance Board, the Health Care Efficiency Research Program and the Ministry of Health will be clarified. Furthermore, the conditions needed to optimize the assessment – appraisal interplay are described and critically evaluated. HTA information is not considered relevant only for the package decisions and advise to the MOH. IMPLEMENTATION STRATEGY: Other parties in the health system, including providers, insurers and patients are also increasingly making use of it. Ways and means of making the information, from the two organizations, accessible and understandable for other users will be presented. RESULTS: and LESSONS LEARNED: Finally, internationalization of the research methodology and results will be reviewed, as well as use of this knowledge in the Netherlands.
Conference/Value in Health Info
2009-10, ISPOR Europe 2009, Paris, France
Value in Health, Vol. 12, No. 7 (October 2009)
Code
CASE4
Topic
Economic Evaluation, Health Policy & Regulatory
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Reimbursement & Access Policy
Disease
Multiple Diseases